Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Orifarm AS
AS
Active
Org 979996233
Sandakerveien 138, 0484
Oslo
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 1998 · 28 years old
18 employees
Monitor
Share
Norway
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
Orifarm AS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
NOK millions
563M
422M
281M
141M
0M
2020: 258M
258M
2020
2021: 396M (+53% vs 2020)
396M
+53%
2021
2022: 452M (+14% vs 2021)
452M
+14%
2022
2023: 402M (-11% vs 2022)
402M
-11%
2023
2024: 371M (-8% vs 2023)
371M
-8%
2024
EBITDA
NOK millions
11M
8M
6M
3M
0M
2020: 7M
7M
2020
2021: 8M (+14% vs 2020)
8M
+14%
2021
2022: 9M (+13% vs 2021)
9M
+13%
2022
2023: 8M (-11% vs 2022)
8M
-11%
2023
2024: 8M (0% vs 2023)
8M
0%
2024
Income statement
NOK thousands
Item
2024
2023
2022
2021
2020
Revenue
370 697
402 243
452 306
396 487
257 865
Staff expenses
−5 611
−2 309
−5 629
−4 415
−4 693
EBITDA
8 307
8 308
8 808
8 127
6 977
Depreciation & amort.
−3 674
−4 237
−4 285
−4 559
−4 669
EBIT
4 634
4 072
4 523
3 568
2 308
Net financials
1 778
1 062
−927
−975
1 038
Profit before tax
6 412
5 134
3 596
2 593
3 347
Tax
1 505
1 202
856
638
832
Net profit
4 907
3 932
2 739
1 956
2 515
Balance sheet
NOK thousands
Item
2024
2023
2022
2021
2020
Total assets
60 920
231 671
100 340
97 629
66 075
Equity
12 883
24 276
20 344
20 105
18 150
Long-term debt
788
914
981
983
862
Short-term debt
47 249
206 481
79 014
76 541
47 063
Total debt
48 036
207 395
79 995
77 524
47 926
Financial ratios
5-year trend
EBITDA margin
2,2 %
This company
15,8 %
Market median
This company
Market median
86% below market
2020
2024
Equity ratio
21,1 %
This company
38,2 %
Market median
This company
Market median
45% below market
2020
2024
Return on equity
38,1 %
This company
18,4 %
Market median
This company
Market median
107% above market
2020
2024
Net profit margin
1,3 %
This company
8,1 %
Market median
This company
Market median
84% below market
2020
2024
Asset turnover
6,09×
This company
1,12×
Market median
This company
Market median
444% above market
2020
2024
Debt / equity
3,73×
This company
0,62×
Market median
This company
Market median
502% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
More on Orifarm AS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
